BR112016016937A8 - partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t - Google Patents
partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula tInfo
- Publication number
- BR112016016937A8 BR112016016937A8 BR112016016937A BR112016016937A BR112016016937A8 BR 112016016937 A8 BR112016016937 A8 BR 112016016937A8 BR 112016016937 A BR112016016937 A BR 112016016937A BR 112016016937 A BR112016016937 A BR 112016016937A BR 112016016937 A8 BR112016016937 A8 BR 112016016937A8
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- cell
- virus
- suspension
- isolated suspension
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 3
- 239000002245 particle Substances 0.000 title 2
- 239000012528 membrane Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000009897 systematic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929651P | 2014-01-21 | 2014-01-21 | |
| PCT/US2015/012160 WO2015112541A2 (en) | 2014-01-21 | 2015-01-21 | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016016937A2 BR112016016937A2 (pt) | 2017-08-08 |
| BR112016016937A8 true BR112016016937A8 (pt) | 2018-12-18 |
Family
ID=53682115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016016937A BR112016016937A8 (pt) | 2014-01-21 | 2015-01-21 | partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170176435A1 (enExample) |
| EP (1) | EP3096774B1 (enExample) |
| JP (1) | JP6875126B2 (enExample) |
| KR (1) | KR102488477B1 (enExample) |
| CN (1) | CN106132428B (enExample) |
| AU (1) | AU2015209540B2 (enExample) |
| BR (1) | BR112016016937A8 (enExample) |
| CA (1) | CA2936352A1 (enExample) |
| IL (1) | IL246685B (enExample) |
| SG (1) | SG11201605632SA (enExample) |
| WO (1) | WO2015112541A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013557B1 (pt) | 2012-12-11 | 2021-12-14 | Albert Einstein College Of Medicine | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| JP7250677B2 (ja) | 2016-12-22 | 2023-04-03 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102619015B1 (ko) | 2017-03-15 | 2023-12-28 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| US11407806B2 (en) | 2017-04-06 | 2022-08-09 | Albert Einstein College Of Medicine | Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells |
| GB201706121D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| CN107099603A (zh) * | 2017-05-31 | 2017-08-29 | 成都克里斯博生物科技有限公司 | 肿瘤免疫t细胞检测试剂盒和检测方法 |
| MX2020002596A (es) * | 2017-09-07 | 2020-07-20 | Cue Biopharma Inc | Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. |
| CA3074839A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| IL316576A (en) * | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| KR20220012291A (ko) | 2019-05-23 | 2022-02-03 | 메사추세츠 인스티튜트 오브 테크놀로지 | 레트로바이러스 표면 디스플레이를 통한 리간드 발견 및 유전자 전달 |
| WO2021178975A1 (en) * | 2020-03-06 | 2021-09-10 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2022159866A2 (en) * | 2021-01-25 | 2022-07-28 | The Regents Of The University Of California | Methods and compositions for the labeling and selection of antigen-specific t-cells |
| JP2024507996A (ja) | 2021-02-26 | 2024-02-21 | ケロニア セラピューティクス， インコーポレイテッド | リンパ球を標的とするレンチウイルスベクター |
| US20240425823A1 (en) * | 2021-10-27 | 2024-12-26 | The Penn State Research Foundation | Universal stem cell and uses thereof |
| US12403194B2 (en) | 2023-09-25 | 2025-09-02 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US12269882B1 (en) | 2023-09-25 | 2025-04-08 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1287363A2 (en) * | 2000-05-25 | 2003-03-05 | Sunol Molecular Corporation | Modulation of t-cell receptor interactions |
| WO2002099089A1 (en) * | 2001-06-04 | 2002-12-12 | Corixa Corporation | Compositions and methods for high-level, large-scale production of recombinant proteins |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| US8895020B2 (en) * | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| AU2003901876A0 (en) * | 2003-04-17 | 2003-05-08 | The Macfarlane Burnet Institute For Medical Research And Public Health | Viral vector |
| CA2567814C (en) * | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| WO2007136778A2 (en) * | 2006-05-19 | 2007-11-29 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
| EP1889851A1 (en) * | 2006-08-18 | 2008-02-20 | Charite Universitätsmedizin-Berlin | PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies |
| EP2184070A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| WO2012127464A2 (en) * | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| WO2014083004A1 (en) * | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
-
2015
- 2015-01-21 CN CN201580011839.8A patent/CN106132428B/zh not_active Expired - Fee Related
- 2015-01-21 CA CA2936352A patent/CA2936352A1/en active Pending
- 2015-01-21 JP JP2016546026A patent/JP6875126B2/ja not_active Expired - Fee Related
- 2015-01-21 US US15/110,384 patent/US20170176435A1/en not_active Abandoned
- 2015-01-21 AU AU2015209540A patent/AU2015209540B2/en not_active Ceased
- 2015-01-21 SG SG11201605632SA patent/SG11201605632SA/en unknown
- 2015-01-21 WO PCT/US2015/012160 patent/WO2015112541A2/en not_active Ceased
- 2015-01-21 EP EP15740849.3A patent/EP3096774B1/en active Active
- 2015-01-21 BR BR112016016937A patent/BR112016016937A8/pt not_active Application Discontinuation
- 2015-01-21 KR KR1020167022488A patent/KR102488477B1/ko active Active
-
2016
- 2016-07-10 IL IL246685A patent/IL246685B/en active IP Right Grant
-
2022
- 2022-05-27 US US17/827,024 patent/US20230052675A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017506882A (ja) | 2017-03-16 |
| AU2015209540A8 (en) | 2016-08-18 |
| EP3096774A2 (en) | 2016-11-30 |
| WO2015112541A2 (en) | 2015-07-30 |
| CA2936352A1 (en) | 2015-07-30 |
| KR20170002366A (ko) | 2017-01-06 |
| JP6875126B2 (ja) | 2021-05-19 |
| AU2015209540B2 (en) | 2021-05-13 |
| CN106132428A (zh) | 2016-11-16 |
| KR102488477B1 (ko) | 2023-01-13 |
| SG11201605632SA (en) | 2016-08-30 |
| CN106132428B (zh) | 2021-08-06 |
| US20170176435A1 (en) | 2017-06-22 |
| WO2015112541A3 (en) | 2015-12-03 |
| WO2015112541A8 (en) | 2016-09-09 |
| EP3096774B1 (en) | 2021-03-24 |
| IL246685B (en) | 2020-03-31 |
| US20230052675A1 (en) | 2023-02-16 |
| IL246685A0 (en) | 2016-08-31 |
| AU2015209540A1 (en) | 2016-07-28 |
| EP3096774A4 (en) | 2017-09-06 |
| BR112016016937A2 (pt) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016016937A8 (pt) | partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t | |
| BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
| BR112018002600A2 (pt) | células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38 | |
| BR112016015399A2 (pt) | método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico | |
| IL251261A0 (en) | Reagents and methods for the identification, enrichment and/or expansion of antigen-specific T-cells | |
| BR112016023625A2 (pt) | dispositivos fluídicos, sistemas e métodos para encapsular e particionar reagentes, e aplicações dos mesmos | |
| CR20180435A (es) | Sistema y método para la verificación de la autenticidad de la información de documentos | |
| MX2018008345A (es) | Proteínas quiméricas y métodos de inmunoterapia. | |
| MX387985B (es) | Particulas tipo virus modificadas de cmv. | |
| BR112015021281A2 (pt) | métodos de recuperação de césio ou rubídio de minério secundário | |
| AR105187A1 (es) | Aparato, método y sistema para preparación automatizada de explantes y método de uso | |
| EP3210130A4 (en) | Data clustering system, methods, and techniques | |
| MX2016016713A (es) | Procesos y sistemas para el montaje de secuencias de acido nucleico. | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| MX387400B (es) | Células de mamífero que expresan antígenos de citomegalovirus. | |
| EP3770604A3 (en) | Flow cytometry method for evaluating biological material for unassociated virus-size particles of influenza virus viral type | |
| EP3186392A4 (en) | In-field dna extraction, detection and authentication methods and systems therefor | |
| EP3206132A4 (en) | File access method, system and host | |
| MX378905B (es) | Pestivirus. | |
| EP3241298A4 (en) | Systems and methods for information recovery from redundancy version packets | |
| BR112017013613A2 (pt) | reator quiímico catalítico com separação de partículas e separador de partículas | |
| SG10201807572PA (en) | Robust antibody purification | |
| MX2016013584A (es) | Parvovirus porcino. | |
| EP4019625C0 (en) | GENETICALLY MODIFIED MULTI-COMPONENT SYSTEM USED FOR SELECTION OF MODIFIED T-CELL RECEPTORS, T-CELLS AND ANTIGEN-PRESENTING CELLS. | |
| BR112015004629A2 (pt) | polipeptídeos de clostridium difficile como vacinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |